News
Biohit Oyj’s Financial Reporting and Annual General Meeting in 2019
30.11.2018 14:48
Biohit Oyj B-shares Subscribed with Stock Options I 2013
05.11.2018 09:30
Stina Syrjänen resigns from Biohit Oyj’s Board of Directors
16.10.2018 12:23
Groundbreaking Diagnostics
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”.
Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare.
Study Protocols
Biohit shares study protocols, i.e., descriptions of clinical studies designed for validation of Biohit Oyj’s diagnostic tests as well as for evaluation of therapeutic efficacy of Biohit’s Acetium capsule and lozenge products in current and novel clinical indications.
Innovations
Biohit's products and services are safe, ethical and costefficient innovations for diagnosing and preventing gastrointestinal diseases and the associated risks.
- About Us
- Scientific
- GastroPanel Research
- Prevalence of H. pylori Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan
- Finnish FIT test for more efficient screening of colorectal cancer
- A simple blood test reveals whether the stomach is healthy or not
- Acetium Research
- Reseach information on Acetium
- Acetaldehyde, Group I human carcinogen
- Scientific Committee on Consumer Safety - Opinion on Acetaldehyde
- State of the art GastroPanel and Acetium innovations for the unmet need
- GastroPanel indications
- Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers
- Presentations
- Key Biohit studies
- Literature
- Study Protocols
- Laboratory Services
- Products
- Partnering
- Investors
- Contact Us